HealthSonix to Conduct Clinical Trials with ZingiberRx for Complex Regional Pain Syndrome (CRPS)
14:50 12.03.08
IRVINE, Calif.--(BUSINESS WIRE)--
HealthSonix, Inc. (OTC:HSXI)(FWB:H7S) today announced that it has strong evidence that ZingiberRx Joint and Muscle Cream with ginger oil can provide pain relief for people with Complex Regional Pain Syndrome (CRPS), also referred to as Reflex Sympathetic Dystrophy (RSD).
The main symptom of CRPS is intense chronic pain, often described as burning pain. Additional signs and symptoms include localized swelling; changes in skin temperature and color; joint stiffness; muscle spasms, weakness and loss (atrophy); and decreased range of motion.
We have been testing ZingiberRx with a CRPS group and the on-going positive feedback we get from the participants has led to the decision to conduct a formal scientific study for this condition, said Dieter D. Doederlein, Vice President Corporate Development for HealthSonix.
Members of our St Catharines CRPS support group had excellent outcomes from the ZingiberRx samples you provided. You definitely should consider a clinical trial, said Helen Small, President of PARC, a national support group that is Promoting Awareness of RSD and CRPS in Canada.
According to the Mayo Clinic, many cases of complex regional pain syndrome occur after a forceful trauma to an arm or a leg, as a result of motor vehicle accidents, shrapnel blasts and other traumas - such as surgery, heart attacks, infections, fractures and sprained ankles. This could open up a whole new market for ZingiberRx, added Doederlein.
HealthSonix, Inc. (OTC: HSXI)(FWB: H7S) is a publicly traded research oriented medical technology company that develops and markets medical devices and healthcare products for institutional and consumer use. The companys patent pending medical devices deliver sound pressure waves to the human body for relief of pain and other musculoskeletal conditions. The focus is on arthritis, athletic injuries and conditions where acute or chronic pain is the cardinal symptom.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
(c)2007 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Zurück
Weiter
